June 27 is National HIV Testing Day, which promotes testing as an important strategy to prevent and control transmission of human immunodeficiency virus (HIV) in the United States. Knowing HIV status at an early stage of infection allows persons to receive appropriate monitoring, treatment, and supportive health care that can extend their lives. Early diagnosis of HIV infection can delay progression to acquired immunodeficiency syndrome (AIDS) and reduce transmission of HIV to others. Nonetheless, in 2006, an estimated 232,700 persons, 21% of those living with HIV infection in the United States, were not aware of their HIV infection status (1) .
To enable earlier diagnosis of HIV infection, CDC recommends that all persons aged 13-64 years be offered voluntary HIV testing routinely during health-care visits and that persons at greater risk for HIV be tested more frequently (e.g., at least annually for sexually active men who have sex with men) (2) . CDC has increased HIV testing opportunities nationwide, notably in areas with the largest number of AIDS cases among African Americans, to reach those at highest risk for acquiring HIV (3) . Additional information on HIV testing resources is available at http://www.hivtest.org.
received an AIDS diagnosis from 1 to 3 years after their HIV diagnosis. Compared with whites, greater percentages of persons of all other racial/ethnic populations received an AIDS diagnosis <3 years after their initial HIV diagnosis. These findings underscore the need for comprehensive HIV testing programs that include both routine screening of persons aged 13-64 years and more frequent testing for persons at increased risk and, therefore, in greater need of periodic HIV testing.
HIV infection and AIDS are notifiable health conditions in all 50 states, the District of Columbia, and five U.S. territories. Although all states have had AIDS reporting since the early 1980s, states have implemented HIV infection reporting over time; national HIV surveillance § with uniform reporting was not implemented fully until 2008. CDC regards data from states with confidential, name-based, HIV surveillance systems sufficient to monitor trends and estimate risk behaviors for HIV infection after 4 years of reporting (3) . The HIV and AIDS diagnosis data in this report were obtained from the 34 states with such reporting since December 2003.
A standardized Kaplan-Meier method was used to examine time from initial HIV diagnosis to AIDS diagnosis for persons receiving HIV diagnoses in the 34 states during 1996-2005. Patients were included in the analysis if the diagnoses of HIV and AIDS they received met the 1999 case definitions (4). Patients were followed up through 2006, and cases were reported to CDC by June 2008. Completeness of AIDS reporting is estimated to be >85%, and duplicate reports are estimated to be <5% (3, 5) . Estimates of the percentage of persons with HIV who had an AIDS diagnosis at 1 year and 3 years after their initial HIV diagnosis were calculated overall and by age group at HIV diagnosis, race/ethnicity, sex, HIV transmission category, and year of HIV diagnosis. Certain patients did not have a full 3 years of follow-up, but all had the minimum 1 year of follow-up. In time-to-event analyses, persons are followed starting at different times, but the results are analyzed at a single point in time. This analysis results in persons with varying lengths of follow-up but enables use of all available data. In this report, persons identified as Hispanic or Latino might be of any race. Persons identified as American Indian or Alaska Native, Asian, black or African American, Native Hawaiian or other Pacific Islander, white, or of multiple or unknown race all were non-Hispanic. Persons aged >13 years were classified according to CDC's standard HIV transmission categories. ¶ § Additional information available at http://www.cdc.gov/hiv/topics/surveillance/ resources/reports/2007report/technicalnotes.htm. ¶ HIV transmission categories: 1) male-to-male sexual contact (e.g., men who have sex with men), 2) injection-drug use, 3) both male-to-male sexual contact and injection-drug use, 4) high-risk heterosexual contact (i.e., with a person known to have HIV or an HIV risk factor [e.g., male-to-male sexual contact or injection-drug use], and 5) other modes of infection (e.g., receipt of blood transfusion or tissue transplant).
Of the 281,421 persons receiving diagnoses of HIV infection during 1996-2005, 45.0% had an AIDS diagnosis by 3 years after their initial HIV diagnosis (Table) . At 3 years after HIV diagnosis, the percentage of persons with an AIDS diagnosis was greater among those who were older (63.2% for those aged >60 years and 57.5% for those aged 50-59 years) when they received their initial HIV diagnosis than among those who were younger (31.6% for those aged 20-29 years and 22.7% for those aged 13-19 years). Whites were least likely to have an AIDS diagnosis 3 years after their initial HIV diagnosis (42.6%), followed by persons identified as of multiple or unknown race (42.9%), persons identified as black or African American (46.1%), American Indian or Alaska Native (47.2%), Hispanic or Latino (48.4%), and Asian (50.4%). Percentages of those with AIDS 3 years after their HIV diagnosis could not be calculated for Native Hawaiians or other Pacific Islanders because of small case numbers (Table) .
At 3 years after their initial HIV diagnosis, 46.9% of men had an AIDS diagnosis compared with 41.5% of women. A similar pattern was observed by HIV transmission category. A greater percentage of male injection-drug users (IDUs) (49.9%) had an AIDS diagnosis at 3 years than female IDUs (41.9%) and a greater percentage of men with high-risk heterosexual contact (50.2%) than women with high-risk heterosexual contact (40.9%). Among those who had male-to-male sexual contact, 47.8% had an AIDS diagnosis after 3 years and among those who had both male-to-male sexual contact and injection-drug use, 47.2% had an AIDS diagnosis.
Persons who received an HIV diagnosis in 2003 were less likely (44.5%) to have an AIDS diagnosis 3 years later than persons diagnosed with HIV in 1996 (49.1%). In addition, persons who received an HIV diagnosis in 2005 were less likely (36.4%) to have an AIDS diagnosis 1 year later than persons diagnosed with HIV in 1996 (43.2%).
Reported by: RL Shouse, MD, T Kajese, MSPH, HI Hall, PhD, LA Valleroy, PhD, Div of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.
Editorial Note: Current estimates suggest that 21% of HIV infections in the United States are undiagnosed (6) . To identify all HIV infections and to initiate early intervention effectively, CDC recommends routine screening for persons aged 13-64 years and pregnant women and retesting at least annually for all persons likely to be at high risk** for HIV (7) . The prognosis for a patient diagnosed with AIDS has improved substantially since introduction of highly active antiretroviral medications (8) ; however, persons who receive a diagnosis late in their course of HIV infection often are more severely immunosuppressed and more likely to experience increased morbidity and shortterm mortality than persons with earlier diagnoses in addition to being more likely to transmit HIV when unaware of their infection (7, 9) .
These findings suggest that from 1996 to 2005 a substantial percentage of persons were diagnosed late in their HIV infection; 38.3% of persons with HIV diagnoses had an AIDS diagnosis within 1 year, and 45.0% had an AIDS diagnosis within 3 years. Because the probability of progression to AIDS following HIV infection in the absence of therapy is approximately 2% in the first 2 years and increases to approximately 50% at 10 years, a diagnosis of AIDS within 1 year of the initial HIV diagnosis suggests late testing for HIV infection and not more rapid advancement to AIDS (1) . A diagnosis of AIDS within 3 years from initial HIV diagnosis suggests late testing but also might reflect limited access to medical care, suboptimal treatment, failure to adhere to treatment, or treatment failure. To optimize clinical management and selection and timing of therapy, the U.S. Department of Health and Human Services issued guidelines for use of antiretroviral agents in April 1998, with the most recent update in November 2008. † † Understanding how factors such as late testing contribute to the high rates of HIV infection among minorities is important to reduce HIV transmission and morbidity and mortality in these populations. This analysis showed that, compared with whites, greater percentages of persons in other racial/ethnic populations had an AIDS diagnosis within 3 years of their initial HIV diagnosis. This finding follows recent reports that HIV incidence and prevalence are higher among minorities (especially blacks or African Americans and Hispanics or Latinos) and provides another facet of the disproportionate effects of HIV infection on these populations (3, 6) . Additional findings in this report showed that men (overall and within transmission categories including both sexes) were more likely than women and older persons were more likely than younger persons to receive a diagnosis of AIDS at 3 years after their HIV diagnosis. Women might receive testing for HIV infection more regularly than men because of more frequent health-care visits and being offered HIV testing as part of routine reproductive health care (e.g., family planning visits).
The findings in this report are subject to at least three limitations. First, the data used to examine time to AIDS diagnosis after initial HIV diagnosis only include data from the 34 states with confidential, name-based HIV surveillance since December 2003. The data from these 34 states account for approximately 66% of the nation's AIDS diagnoses but 
HIV Testing Among High School Students -United States, 2007
In the United States, an estimated 1.1 million persons were living with human immunodeficiency virus (HIV) infection in 2006, of whom an estimated 232,700 were undiagnosed and unaware they were HIV infected (1). Adolescents and young adults aged 13-24 years represented 4.4% of the total but disproportionately comprised an estimated 9.9% of the undiagnosed cases (1) . Early diagnosis of HIV infection facilitates medical interventions and enables infected persons to reduce high-risk behavior and the likelihood of further HIV transmission. To determine the extent to which adolescents are being tested for HIV, data from the 2007 Youth Risk Behavior Survey (YRBS) (the most recent data available) were analyzed. The results indicated that nationwide, 12.9% of all high school students had ever been tested for HIV. The prevalence of HIV testing increased with increasing grade and decreased with increasing age at first sexual intercourse. Prevalence of HIV testing was higher among female students (14.8%) than male students (11.1%), higher among non-Hispanic black students (22.4%) than Hispanic (12.7%) and non-Hispanic white students (10.7%), was higher among students who had ever had sexual intercourse (22.3%) than those who had never had sexual intercourse (4.0%), and among students who had ever had sexual intercourse. To decrease the number of undiagnosed HIV infections among adolescents and promote HIV prevention, CDC recommends that health-care providers offer HIV screening as part of routine medical care. High schools can support those screening efforts by including information on obtaining HIV testing in their HIV curricula.
YRBS, a component of CDC's Youth Risk Behavior Surveillance System,* estimates the prevalence of health risk behaviors among high school students through biennial national, state, and local surveys. The 2007 national survey obtained cross-sectional data representative of public-and private-school students in grades 9-12 in the 50 states and might not be nationally representative. Data from additional states are expected to be added in the future, including states (e.g., California) with high HIV prevalence and heavy concentrations of certain populations (e.g., Hispanics). Second, misclassification of the HIV diagnosis date might have occurred in certain cases. For example, some persons might have had positive results from anonymous, unreported HIV tests before they had a confidential HIV test which was reported to a health department, making the time from initial HIV diagnosis to AIDS diagnosis appear shorter than was actually the case. Finally, the reasons for late HIV testing cannot be discerned from the results of this study; therefore, in addition to promoting early testing, comprehensive strategies to improve medical care access, enhance compliance, and ensure appropriate timing and selection of effective therapy also should be considered.
To reduce late testing for HIV infection, health-care providers should fully implement both routine and risk-based HIV testing, and local public health officials should continue educational efforts regarding the importance of early HIV testing. In 2003, CDC launched an initiative, Advancing HIV Prevention: New Strategies for a Changing Epidemic. Priority strategies included making HIV testing part of routine medical care and implementing new models to diagnose HIV infection outside of clinical settings. From this initiative, CDC sponsored multiple projects that demonstrated the feasibility and yield of HIV screening programs in health-care, corrections, and community settings (10). Achieving earlier diagnosis and reducing HIV transmission will require providers, health departments, and community organizations to promote screening in healthcare settings and periodically retest persons with ongoing risk behaviors. Additionally, expansion of efforts within the social networks of persons who receive an HIV diagnosis can result in testing of others who are likely infected.
the District of Columbia. Students completed an anonymous, self-administered questionnaire that included a question about HIV testing. † Students from 157 schools completed 14,103 questionnaires. The school response rate was 81%, the student response rate was 84%, and the overall response rate was 68%. § After quality control measures, data from 14,041 students were available for analysis; 12,120 (86.3%) students answered the HIV testing question. A more detailed description of YRBS methods has been published (2) .
For this analysis, data were weighted to adjust for nonresponse and oversampling of black and Hispanic students. Analyses were conducted on weighted data using statistical software to account for the complex sample design (2). T-tests were used to determine statistically significant differences in HIV testing by sex, race/ethnicity, whether students had been taught in school about acquired immunodeficiency syndrome (AIDS) or HIV infection, ¶ and whether students had ever had sexual intercourse.** The Cochran-Mantel-Haenszel trend test was used to determine statistically significant differences in HIV testing by grade and age when students had first sexual intercourse. † † Race/ethnicity data are presented only for nonHispanic black, non-Hispanic white, and Hispanic students (who might be of any race).
The analysis showed that, nationwide, 12.9% of students had ever been tested for HIV (excluding tests for blood donation) ( Table 1) . Overall, the prevalence of HIV testing was higher among female students (14.8%) than male students (11.1%; p<0.001), higher among non-Hispanic black students (22.4%) than Hispanic students (12.7%; p<0.001) and non-Hispanic white students (10.7%; p<0.001), and increased by grade from 9.1% among 9th-grade students to 18.9% among 12th-grade students (p<0.001). HIV testing also was more common among students who had ever been taught in school about AIDS or HIV infection (13.2%) than among those who had not (9.7%; p<0.001), and higher among students who ever had sexual intercourse (22.3%) than among students who had not (4.0%; p<0.001). Among students who had ever had sexual intercourse, the prevalence of HIV testing decreased by age at first sexual intercourse, from 30.7% among students who first had sexual intercourse before age 13 years to 12.6% among students who first had sexual intercourse at age 17 years or older (p<0.001). The prevalence of HIV testing increased with increasing grade among non-Hispanic white female students (p<0.001), non-Hispanic black female students (p<0.001), Hispanic female students (p=0.02), and non-Hispanic black male students (p=0.002) ( Table 2 ). Among students who ever had sexual intercourse, the prevalence of HIV testing increased with increasing grade among non-Hispanic white female students (p=0.02), non-Hispanic black female students (p=0.003), Hispanic female students (p=0.01), and non-Hispanic black male students (p=0.002). The prevalence of HIV testing was (4) . This analysis indicated that non-Hispanic black students had the highest overall race/ethnicity-specific percentage of students tested (22%), and among all students who had sexual intercourse, non-Hispanic black students in 12th grade had the highest testing prevalence. These findings suggest that, with respect to race/ethnicity, students with the highest group risk are getting tested at higher rates. Visits to health-care providers are opportunities for HIV testing. Data collected during 1994-1996 for the National Longitudinal Study of Adolescent Health reveal that two thirds of adolescents aged 15-17 years had a physical examination in the preceding 12 months (5). In the 2000 National Survey of Teens, two thirds of the adolescents who reported being tested for HIV had asked to be tested, and most had been tested in health-care settings, including general health clinics (50%), private physician offices (31%), and HIV clinics (9%) (3).
In 2006, CDC recommended routine HIV screening for all patients aged 13-64 years (6) . Certain persons at high risk for HIV should be tested at least annually: 1) injection-drug users and their sex partners, 2) persons who exchange sex for money or drugs, 3) sex partners of HIV-infected persons, and 4) men who have sex with men or heterosexual persons who have had more than one sex partner since their most recent HIV test or whose sex partners have had more than one sex partner since their most recent HIV test. In addition, all patients seeking treatment for STDs and those attending STD clinics should be 
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screened routinely for HIV during each visit for a new health concern, regardless of known or suspected risk behaviors for HIV infection. The Society for Adolescent Medicine recommends offering testing and effective risk-reduction counseling and assistance as part of routine care of sexually active adolescents, especially those who live in high HIV prevalence areas (7) . The American College of Obstetricians and Gynecologists also recommends HIV screening for sexually active women aged <19 years (8) .
Although the results of this report show that the prevalence of HIV testing was higher among female than male students and increased with increasing grade, 73% of female students who had sexual intercourse had never been tested for HIV.
Routine HIV screening in health-care settings, as recommended, could increase the proportion of adolescents who are tested for HIV among those who receive medical care. Adolescents who have had sexual intercourse or are considering having sexual intercourse should know their HIV status and the HIV status of their sex partners (6) . Previously published YRBS data for 2007 showed that 15% of high school students had had sexual intercourse with four or more persons during their lifetime (2) . Such students and adolescents at high risk for HIV infection should be tested at least annually (6) .
The findings in this report are subject to at least three limitations. First, these results apply only to adolescents who attend school and therefore are not representative of all adolescents. In 2005, of persons aged 16-17 years in the United States, approximately 4% were not enrolled in a high school program and had not completed high school (9) . Second, the extent of YRBS underreporting or overreporting of behaviors such as HIV testing or age at first sexual intercourse has not been determined. Third, rates of HIV infection and sexual behaviors vary geographically, and this national analysis cannot be applied to regions, states or cities.
HIV testing among sexually active adolescents is an important strategy to reduce the incidence of HIV infection (6) . The results of this analysis showed that students who had been taught about AIDS or HIV in school were more likely to have had an HIV test than were those who had not been taught about AIDS or HIV. Although approximately 90% of high school students have been taught about AIDS or HIV (2), only 12.9% have had an HIV test. High schools can enhance their HIV prevention curricula by including information on locations and procedures for obtaining free, confidential HIV testing. ¶ ¶ In accordance with state and local policies, school health professionals could refer at-risk students for HIV prevention, counseling, and testing services. Many schools collaborate with local health centers and community-based organizations to help students receive screenings and some school-based health clinics offer HIV testing on-site.*** Health-care providers, educators, and parents or guardians play critical roles in providing support and guidance to adolescents in making decisions about the timing and frequency of HIV testing. Because adolescents might be sexually active but unwilling to discuss this information, health-care providers should provide HIV testing routinely to all patients aged >13 years in accordance with CDC recommendations. ¶ ¶ National HIV and STD testing resources, including locations of testing sites, are available at http://www.hivtest.org, and information about youth-friendly HIV testing, counseling, and care is available at http://www.adolescent aids.org. *** Some examples are available at http://www.cdc.gov/healthyyouth/sexual behaviors/pdf/hivtesting_adolescents.pdf.
Progress Toward the 2012 Measles Elimination Goal -Western Pacific Region, 1990-2008
In 2003, the World Health Organization (WHO) Regional Committee of the Western Pacific Region (WPR) formally declared a measles elimination goal* (1), and in 2005, the committee established a target date of 2012 for regional measles elimination (2) . Key strategies recommended by WHO for achievement of measles elimination include 1) very high (>95%) vaccination coverage with 2 doses of measles-containing vaccine (MCV1 and MCV2) through routine vaccination and/or supplemental immunization activities (SIAs) † ; 2) highquality case-based § measles surveillance; and 3) access to an accredited measles laboratory network for testing of suspected measles cases and identification of measles virus genotypes. This report describes progress toward measles elimination in the WPR through 2008. Measles likely has been eliminated or nearly eliminated in 24 of the 37 countries and areas in the WPR (referred to in this report as countries). However, large numbers of measles cases continue to be reported from several countries. During 2008, a total of 131,441 confirmed measles cases (98.4 per million population) were reported from China and 11,015 cases (86.1 per million population) from Japan, two countries that account for 82% of the region's population and >97% of its confirmed measles cases. Intensified efforts by WPR countries, particularly China and Japan, will be required to achieve the 2012 goal.
Routine Vaccination
Among the 37 countries in the WPR, ¶ 36 report administrative and, if available, survey data and their estimates of vaccination coverage among infants annually to WHO and the United Nations Children's Fund (UNICEF). The other country, Pitcairn Islands (with a population of approximately 50 persons), does not report data to WHO/UNICEF and is not included in this report. Based on these and other data available from published literature, WHO/UNICEF make their estimates of actual vaccination coverage for WHO member states (3). Regional MCV1 coverage by year was determined using WHO/UNICEF estimates of vaccination coverage and, when these estimates were not available (such as in certain areas of member states), coverage was determined using country estimates and weighting by country population size. Because China includes 75% of the region's population, its data are reported separately.
The history of measles elimination in the WPR can be divided into three periods: the period of measles control (1990) (1991) (1992) (1993) (1994) (1995) , the period of accelerated measles control (1996) (1997) (1998) (1999) (2000) (2001) (2002) , and the period of measles elimination (from 2003 to the present).** This report uses these three periods to describe progress toward measles elimination. Among the 35 WPR countries reporting (i.e., all WPR countries except China and Pitcairn Islands), mean regional MCV1 coverage was 80.8% during the period of measles control (1990) (1991) (1992) (1993) (1994) (1995) ** Measles control aims to reduce the number of measles cases and deaths by 1) high (>90%) coverage with a single dose of measles vaccine; 2) measles surveillance in every district with aggregate data reporting; and 3) case management with vitamin A and treatment for measles complications. Accelerated measles control aims to prevent measles outbreaks by providing a second dose of measles vaccine, often through campaigns, and conducting active measles surveillance with laboratory confirmation of suspected outbreaks. Measles elimination aims to interrupt transmission of measles by 1) very high (>95%) coverage with 2 doses of measles vaccine through routine vaccination systems or SIAs; 2) high-quality case-based surveillance; and 3) access to an accredited measles laboratory network for confirmation of suspected measles cases and identification of measles genotypes. † † Papua New Guinea also provides a supplementary dose of MCV at age 6 months.
Surveillance Activities
By 2008, all countries in WPR conducted case-based measles surveillance, supported by the measles and rubella laboratory network (LabNet), a network of 382 laboratories. Standard indicators for high-quality measles surveillance include 1) two or more suspected measles cases per 100,000 discarded as nonmeasles; 2) ≥80% of suspected measles cases with adequate investigations (i.e., investigations within 48 hours of rash onset that include all essential data elements); 3) ≥80% of suspected measles cases with clinical specimens collected within 28 days of rash onset; and 4) ≥80% of specimens with laboratory results available within 7 days after receipt in the laboratory (4, 5) . In 2008, the region's indicator achievements were 1.6, 47%, 62%, and 76%, respectively (6) .
Genotypes of endemic measles virus identified among measles patients in the WPR since 2007 include D5 in Japan, D9 in Lao People's Democratic Republic, Malaysia, and New Zealand, and H1 in China, Hong Kong (China, Special Administrative Region [SAR]), and Vietnam. In addition, genotypes B3, D4, D8, and G3 were identified among measles patients; some of these genotypes were imported from other regions.
Monitoring Measles Incidence
Suspected measles cases can be confirmed by the laboratory (e.g., presence of anti-measles immunoglobulin M (IgM) antibodies in clinical specimens), by epidemiologic linkage to another confirmed case, and by clinical criteria (i.e., cases that satisfy the measles clinical case definition § § and cannot be discarded as nonmeasles by laboratory or other criteria). Since 1990, the largest annual number of measles cases reported from the WPR (excluding China) was 106,172 (255. administration of MCV2, 12 countries (40%) administered MCV2 at age 13-23 months, three (10%) at age 2 years, eight (26.7%) at age 4 years, one (3.3%) at age 5 years, five (16.7%) at age 6 years, and one (3.3%) at age 7 years. 
Supplemental Immunization Activities

Country Measles Elimination Status
Several WPR countries have achieved or nearly achieved the indicator targets suggesting substantial progress toward measles elimination. In 2006, Republic of Korea declared measles eliminated after having successfully implemented WHO-recommended strategies (8) . In Australia, measles incidence has ranged from 0.5 to 6.1 per million since 2002; case investigations and genotype analysis indicated that the majority of these cases were imported or import-related (9) . Reported routine vaccination coverage in Australia is high; however, sensitivity of suspected measles reporting is uncertain because surveillance performance is not monitored nationally. In Editorial Note: The WPR has made progress toward the 2012 regional goal of measles elimination as evidenced by increasing routine and SIA measles vaccination coverage and declining measles incidence in the presence of improving case-based, laboratory-supported measles surveillance systems. Nevertheless, in the region overall and in many countries, surveillance does not yet meet elimination standards, leading to underreporting or misclassification of cases. Moreover, countries such as Cambodia, Lao People's Democratic Republic, Papua New Guinea, and others face challenges to achieving the 2012 goal because of general weaknesses of public health services that result in low routine vaccination coverage. In such countries, continuing periodic SIAs to attain high MCV coverage while working to strengthen routine vaccination systems will be critical to achieve the goal. Ensuring that all suspected measles cases are identified, reported and fully investigated by providing training, adequate operational costs, and laboratory support is urgently needed to monitor progress toward and ultimately validate achievement of measles elimination. Monitoring of circulating measles genotypes also is needed to validate interruption of endemic measles virus transmission.
Challenges also exist in China and Japan, which together accounted for 82% of the region's population and more than 97% of its reported measles cases in 2008. Both countries have made renewed commitments and plans for achieving the 2012 regional goal. China has strengthened routine measles vaccination by scheduling earlier administration of MCV2 (at age 18-24 months instead of 7 years), providing incentives to health-care workers for immunizing children, and requiring proof of receiving 2 doses of measles vaccine at school entry. Japan is implementing a national measles elimination plan established in December 2007 (7) .
Efforts to eliminate measles help strengthen health systems and reduce child mortality from pneumonia, diarrhea, and micronutrient deficiencies that occur after measles infection, thereby helping to achieve the United Nations' Millennium Development Goal No. 4 (to reduce by two thirds, from 1990 to 2015, the mortality rate in children aged <5 years). ¶ ¶ To achieve measles elimination and Millennium Development Goal No. 4, intensified and innovative efforts will be required by WPR countries and measles elimination partners*** to implement recommended strategies and target potentially new high-risk groups (e.g., young adults) revealed by epidemiologic analysis of surveillance data. vaccine booster dose administered to most healthy children at age 12-15 months (1-5). Production of Merck Hib vaccine products is still suspended. However, two other Hib-containing vaccines manufactured by Sanofi Pasteur have been available for use in the United States during this shortage: monovalent Hib vaccine (ActHIB) and DTaP-IPV/Hib (Pentacel). Beginning in July 2009, the manufacturer of these two vaccines will increase the number of doses of these two products available for use in the United States, which will result in the supply being sufficient to reinstate the Hib vaccine booster dose.
Updated Recommendations for Use of Haemophilus influenzae
Reinstatement of Hib Booster Dose
Effective immediately, CDC, in consultation with ACIP, AAFP, and AAP, is recommending reinstatement of the booster dose of Hib vaccine for children aged 12-15 months who have completed the primary 3-dose series. Infants should continue to receive the primary Hib vaccine series at ages 2, 4, and 6 months. Children aged 12-15 months should receive the booster dose on time. Older children for whom the booster dose was deferred should receive their Hib booster dose at the next routinely scheduled visit or medical encounter. Although supply is sufficient to reinstate the booster dose and begin catch-up vaccination, supply is not yet ample enough to support a mass notification process to contact all children with deferred Hib booster doses. Sufficient vaccine will be available to administer the primary series at ages 2, 4, and 6 months and a booster dose on time to children aged 12-15 months. As part of delivering the booster dose to those children for whom it was deferred at the next routinely scheduled appointment or medical encounter, practices should discuss with parents the reasons for the change in recommendation and might consider 1) reviewing electronic or paper medical records or immunization information system records to identify children in need of a booster dose before physician encounters, 2) evaluating children's vaccination status during their scheduled visit, and 3) sharing immunization schedules with parents to make them aware of this plan.
Use of Combination Vaccines
During the Hib shortage, children received protection from certain vaccine preventable diseases in their primary vaccination series through various permutations of available combination vaccines (e.g., DTaP-IPV/Hib [Pentacel] and DTaP-IPV-HepB [Pediarix]) and monovalent vaccines (e.g., ActHib, HepB, and IPV). Therefore, a mismatch might exist between patient vaccination needs and the available stock of different vaccine formulations (e.g., combination products versus single-antigen vaccines) in local provider offices. This situation presents a challenge for providers to administer vaccines to ensure appropriate coverage while minimizing extra doses of unneeded vaccine. For example, if a provider is using DTaP-IPV/Hib (Pentacel) vaccine to protect infants against Hib disease, the provider should ensure that adequate stock of monovalent HepB vaccine is available to complete the HepB vaccine series.* Children who need the Hib booster and who already have received 4 doses of DTaP should receive monovalent Hib vaccine (ActHIB) as their Hib booster dose. However, if DTaP-IPV/Hib is the only Hib-containing vaccine available, this combination product can be used to complete the series of Hib vaccination, even if the child already has received all the necessary doses of DTaP and IPV.
Information Regarding ActHIB or Pentacel
Vaccination providers with questions about their supplies of monovalent Hib vaccine (ActHIB) or DTaP-IPV/Hib (Pentacel) purchased with nonpublic funds should contact Sanofi Pasteur's customer service department (telephone, 800-822-2463). Sanofi Pasteur will work directly with physicians to increase allotments of Hib-containing vaccines on the basis of previous purchasing patterns or practice birth cohort and estimates of additional vaccine doses needed. (ICD-9) . This resulted in approximately 5% fewer deaths being classified as motor-vehicle traffic-related deaths and 2% more deaths being classified as poisoning-related deaths. Therefore, death rates for 1998 and earlier are not directly comparable with those computed after 1998. Little change was observed in the classification of firearm-related deaths from ICD-9 to ICD-10.
Motor-vehicle traffic, poisoning, and firearms were the three leading causes of injury deaths in the United States in 2006. Age-adjusted death rates for motor-vehicle traffic-related deaths and deaths from firearms decreased from 1979 to 2006, whereas the rate for poisoning more than doubled during the same period. From 2005 to 2006, the age-adjusted poisoning death rate increased 13%, whereas motor-vehicle traffic and firearm death rates remained unchanged. --0  1  7  17  8  3  Poliomyelitis, paralytic  ------1  -Polio virus infection, nonparalytic  §  -----N  N  N  Psittacosis  §  -6  0  8  12  21  16  12  Q fever total  § ,  ¶ ¶ ¶ :  -28  4  124  171  169  136  70  acute  -26  2  110  ----chronic  -2  0  14  ----Rabies, human  --0  1  1  3  2  7  Rubella****  -1  0  16  12  11  11 10 Rubella, congenital syndrome - Table I footnotes on next page.
* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals. † Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://www.cdc.gov/epo/dhpsi/phs/files/5yearweeklyaverage.pdf. § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, VectorBorne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II . ** The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to E. chaffeensis); Ehrlichiosis, human granulocytic (analogous to Anaplasma phagocytophilum), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of E. ewingii). † † Data for H. influenzae (all ages, all serotypes) are available in Table II . § § Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV , which appears quarterly. ¶ ¶ Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Seventy-six influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported. *** No measles cases were reported for the current week. † † † Data for meningococcal disease (all serogroups) are available in Table II . § § § These cases were obtained from state and territorial health departments in response to the pandemic influenza A (H1N1) virus infections and include both confirmed and probable cases in addition to those reported to the National Notifiable Diseases Surveillance System (NNDSS). Because of the volume of cases and the method by which they are being collected, a 5-year weekly average for this disease is not calculated. ¶ ¶ ¶ In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not differentiated with respect to acute and chronic Q fever cases. **** No rubella cases were reported for the current week. † † † † Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases. Alaska  6  2  10  33  30  11  14  24  338  232  1  0  3  8  11  California  7  35  59  712  849  121  476  657  11,265 12,121  -0  3  12  31  Hawaii  -0  4  5  14  -13  19  265  270  -0  2  13  9  Oregon  §  -7  73  131  199  19  22  48  462  588  -0  16  28  32  Washington  5  9  74  126  116  26  50  81  926  1,537  -0  2  3  2  American Samoa  -0 -2  8  32  60  -1  4  16  40  -2  18  20  45  Connecticut  -0  4  10  11  -0  3  6  13  -0  5  10  8  Maine  §  -0  5  1  3  -0  2  7  8  -0  2  -1  Massachusetts  -1  3  14  30  -0  2  1  12  -1  7  6  17  New Hampshire  -0  2  3  5  -0  2  2  3  -0  5  1  6  Rhode Island  §  -0  2  3  10  -0  1  -3  -0  14  2 -1  13  14  13  -0  3  4  12  1  1  4  37  38  Arizona  -0  2  1  2  -0  2  1  4  -0  2  7  5  Colorado  -0  1  2  2  -0  1  1  3  1  0  2  11  8  Idaho  §  -0  2  5 1  3  13  76  37  -3  10  50  53  -4  14  93  176  Alaska  -0  2  1  1  -0  1  1  2  -0  2  2  3  California  -2  6  67  26  -2  8  38  41  -2  8  58  137  Hawaii  N  0  0  N  N  -0  1  1  2  -0  1  3  1  Oregon  §  -0  4  5  10  -0  3  5  4  -0  10  21  20  Washington  1  0  12  3  --0  3  5 -5  15  103  91  -0  2  2  3  -0  3  8  18  Oregon  §  -7  73  156  156  -1  8  11  11  -1  10  16  25  Washington  27  11  85  264  218  4  3  16  40  25  1  2  13  74  31  American Samoa  -0 N  -3  9  81  61  Florida  -15  36  481  398  -3  13  79  70  -20  31  428  456  Georgia  3  8  25  217  264  1  1  5  28  37  -14  227  252  208  Maryland  §  -0  1 -3  47  19  408  -0  1  -2  -0  1  --Louisiana  -1  4  35  47  -0  3  ---0  5  --Oklahoma  N  0  0  N  N  -0  1  -2  -0  1  -3  Texas  ¶  -47  282  435  5,077  -0  6  -2  -0  4  -4  Mountain  5  24  83  605  1,340  -0  12  -2  -0  22  -6  Arizona  -0  0  ---0  10  -1  -0  8  --Colorado  5  11  44  297  545  -0  4  ---0  10  -4  Idaho  ¶  N  0  0  N  N  -0  1  -1  -0  6  -1  Montana  ¶  -2  27  70  180  -0  0  ---0  2  --Nevada  ¶  N  0  0  N  N  -0  2  ---0  3  --New Mexico  ¶  -2  10  67  135  -0  1  ---0  1  --Utah  -10  31  171  471  -0  2  ---0  5  --Wyoming  ¶  -0  1  -9  -0  0  ---0  2  -1  Pacific  1  3  7  60  60  -0  38  ---0  23  -3  Alaska  1  2  6  40  23  -0  0  ---0  0  --California  -0  0  ---0  37  ---0  20  -3  Hawaii  -1  4 ---------------Guam  -0  3  -55  -0  0  ---0  0  --Puerto Rico  -7  17  114  326  -0  0  ---0 Table IV , which appears quarterly. † Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I . § Not reportable in all states. Data from states where the condition is not reportable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm. ¶ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).
